Key Points
- Si-Bone insider Anshul Maheshwari sold 1,731 shares at an average price of $19.50, generating $33,754.50. The sale covered tax-withholding obligations tied to vested equity awards, leaving him with 218,235 shares.
- Si-Bone shares opened at $19.55, with a market capitalization of approximately $867 million. The company recently reported quarterly revenue of $56.01 million and an EPS loss of $0.09, outperforming analysts’ estimates.
- Analysts maintain a generally positive outlook, with six Buy ratings and one Sell rating, an overall “Moderate Buy” consensus, and an average price target of $24.17. Institutional investors own approximately 98.11% of the stock.
SiBone (NASDAQ:SIBN - Get Free Report) insider Anshul Maheshwari sold 1,731 shares of the company's stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $19.50, for a total transaction of $33,754.50. Following the completion of the transaction, the insider owned 218,235 shares of the company's stock, valued at approximately $4,255,582.50. This trade represents a 0.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Anshul Maheshwari also recently made the following trade(s):
- On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The stock was sold at an average price of $18.18, for a total transaction of $60,321.24.
- On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The shares were sold at an average price of $20.11, for a total value of $233,999.96.
- On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $224,784.56.
- On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The stock was sold at an average price of $19.55, for a total value of $112,353.85.
- On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The stock was sold at an average price of $18.65, for a total value of $87,002.25.
SiBone Stock Performance
Shares of SIBN stock opened at $19.55 on Wednesday. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. SiBone has a 12-month low of $11.48 and a 12-month high of $21.89. The business's 50 day moving average is $18.77 and its two-hundred day moving average is $16.20. The company has a market capitalization of $867.04 million, a P/E ratio of -57.50 and a beta of 0.66.
SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million during the quarter, compared to analysts' expectations of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. Analysts expect that SiBone will post -0.4 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on the stock. Weiss Ratings raised shares of SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, August 20th. UBS Group lifted their target price on shares of SiBone from $24.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. Truist Financial reissued a "buy" rating and set a $23.00 target price (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. Finally, TD Cowen upped their price target on shares of SiBone from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, SiBone presently has an average rating of "Moderate Buy" and an average target price of $24.17.
Read Our Latest Analysis on SIBN
Institutional Trading of SiBone
Several large investors have recently made changes to their positions in the company. First Light Asset Management LLC raised its stake in SiBone by 51.8% in the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company's stock valued at $132,649,000 after purchasing an additional 2,774,795 shares during the last quarter. Squarepoint Ops LLC boosted its stake in SiBone by 40.3% during the 2nd quarter. Squarepoint Ops LLC now owns 118,128 shares of the company's stock worth $1,928,000 after purchasing an additional 33,947 shares during the last quarter. VELA Investment Management LLC grew its holdings in shares of SiBone by 7.4% during the second quarter. VELA Investment Management LLC now owns 201,094 shares of the company's stock worth $3,282,000 after buying an additional 13,934 shares in the last quarter. Corient Private Wealth LP grew its holdings in shares of SiBone by 119.6% during the second quarter. Corient Private Wealth LP now owns 43,946 shares of the company's stock worth $717,000 after buying an additional 23,938 shares in the last quarter. Finally, Versant Capital Management Inc raised its position in shares of SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company's stock valued at $29,000 after buying an additional 887 shares during the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.
SiBone Company Profile
(
Get Free Report)
SI-BONE, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of disorders affecting the sacroiliac joint, which connects the spine to the pelvis. The company's technology is intended to support minimally invasive procedures for patients with sacroiliac joint dysfunction and related conditions.
Its product portfolio includes the iFuse Implant System, a family of triangular titanium implants designed to stabilize and fuse the sacroiliac joint.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
